Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2015 Jan 1.
Published in final edited form as: Curr Gastroenterol Rep. 2014 Jan;16(1):362. doi: 10.1007/s11894-013-0362-0

Useful Tests for Hepatic Encephalopathy in Clinical Practice

Eiman Nabi 1, Jasmohan S Bajaj 2
PMCID: PMC3918211  NIHMSID: NIHMS551299  PMID: 24357348

Abstract

Hepatic encephalopathy (HE) is a serious complication of liver disease and portosystemic shunting that represents a continuum of neuropsychiatric changes and altered consciousness. It is classified as overt hepatic encephalopathy (OHE) when clinically apparent or as covert hepatic encephalopathy (CHE) in its mildest form. Progression of CHE to OHE and its impact of quality of life make its early diagnosis imperative. Several diagnostic techniques ranging from simple clinical scales to sophisticated computerized tests exist yet diagnosis remains a challenge due to the time, cost and personnel involved. Psychometric tests appear promising due to their high sensitivity and low cost but results are variable depending on age and education. The pros and cons of current diagnostic methods for overt and covert HE are reviewed along with strategy to CHE testing.

Keywords: Covert hepatic encephalopathy, minimal hepatic encephalopathy, overt hepatic encephalopathy, ISHEN, cognitive testing, neurophysiological tests, paper-pencil tests, computerized tests, inhibitory control test, critical flicker frequency, psychometric hepatic encephalopathy score (PHES), stroop App, RBANS

INTRODUCTION

Hepatic encephalopathy (HE) is a spectrum of neuropsychiatric abnormalities seen in patients with liver dysfunction and portal-systemic shunting diagnosed after exclusion of other known brain diseases1. It affects 30% to 45% of patients with cirrhosis, and its presence and degree of progression signify poor prognosis and high mortality2. The Working Party at the 11th World Congress of Gastroenterology, Vienna, under the Organization Mondiale de Gastroentrologie proposed a multiaxial definition of HE that defined both the type of hepatic abnormality and the duration and characteristics of neurological manifestations in chronic liver disease. Type A HE is due to acute liver failure, type B is attributable to portosystemic shunt or bypass, and type C is due to cirrhosis. Type C HE can be further subclassified into episodic, persistent, and minimal1.

Based on clinical and neuropsychometric testing, HE can be categorized as overt or covert. HE that is clinically apparent is termed as overt hepatic encephalopathy (OHE). HE that is mild without an obvious clinical profile and diagnosed only by specialized cognitive testing is termed as covert hepatic encephalopathy (CHE), previously known as minimal or subclinical hepatic encephalopathy.

Over the past decade, CHE has received growing interest due to its prognostic importance for the development of OHE3. It has a characteristic cognitive profile that cannot be diagnosed clinically1,46. CHE is known to be associated with deficits in driving skills79, reduction in quality of life10,11, impairment of working capability3,12 and, most importantly, predicting the subsequent onset of overt HE1316. CHE is associated with poor prognosis and is an independent predictor of survival17. In recognition of the dangerous consequences of CHE, the name of the condition has recently been changed from minimal to covert, a position endorsed by the International Society for Hepatic Encephalopathy and Nitrogen Metabolism18.

SEARCH CRITERIA

A PubMed search was conducted using MeSH term “Hepatic Encephalopathy/diagnosis” between dates 1/1/2009 and 31/12/2013 yielding 309 articles total. Articles were reviewed based on their relevance to the topic. The Hepatic Encephalopathy Update: Reports from Recent Conferences 2013 International Liver Conference was also reviewed.

TESTS FOR GRADING THE SEVERITY OF OVERT HEPATIC ENCEPHALOPATHY

CLINICAL DIAGNOSIS

OHE is diagnosed clinically based on two types of symptoms: impaired mental status, as defined by the West Haven Criteria (WHC), and impaired neuromotor function19. The current standard for grading HE is based on clinical diagnosis, hence a thorough history and physical exam are imperative. OHE can be further subdivided into episodic or persistent and precipitated or spontaneously occurring19.

Overt HE remains a diagnosis of exclusion and other causes of altered mentation in cirrhotic patients should be investigated before considering this particular diagnosis.

Ammonia levels

Since ammonia has been regarded as the key precipitating factor, plasma ammonia levels are used widely in patients with cirrhosis and altered mental status to diagnose HE20,21. It represents a common conception that increased ammonia levels in a cirrhotic patient can confirm, or rule out, HE. However, the degree of correlation between ammonia levels and the grading of HE continues to be controversial.

Gundling et al evaluated in a prospective study in an emergency department setting whether elevated blood ammonia levels coincide with HE which was additionally established by the West Haven criteria and the critical flicker frequency, respectively and found that ammonia blood levels do not reliably detect HE. Its use as sole indicator for HE in the Emergency Department may result in frequent misinterpretations22.

Grading of OHE

1. WHC

The well-known West Haven criteria (Conn score) is based upon impairment in consciousness, intellectual function, and behavior1. It classifies HE into five grades of severity. Grade 0 represents patients without detectable changes in personality or behavior, grade I includes patients with trivial lack of awareness, shortened attention span, and altered sleep and mood, and grades II–IV represent overt HE and coma. To avoid missing the lower grades of HE, the presence of HE should be evaluated by using the mini mental status exam (MMSE) that examines memory and attention in a systematic manner.

The WHC is recommended by the Working Party on Hepatic Encephalopathy for assessment of OHE in clinical trials1. In a recent study by Bass et al23 evaluating the efficacy of rifaximin in preventing relapse of HE in patients with overt HE, the investigators used the WHC to grade the stages of HE but failed to mention that the grading was reached by implementing the Hepatic Encephalopathy Scoring Algorithm (HESA) 24.

2. HESA

The Hepatic Encephalopathy Scoring Algorithm (HESA), originally devised for use in a multicenter study by Hassanein et al to assess the utility of extracorporeal albumin dialysis in the treatment of patients with severe HE (grade III/IV), may be particularly useful for assessing patients with low grades of HE, as minimal variability was detected between the scores given at the different study sites25. The HESA combined clinical indicators with those derived from simple neuropsychological tests, the latter more often used in milder grades of HE (grade I/II). The performance of each indicator was compared across grades and sites26. HESA is simple, time efficient and sensitive to subtle brain changes like the WHC but offers a more objective approach, which should yield greater reliability across the spectrum of HE. However the length of HESA makes it difficult to apply in clinical practice.

3. CHESS

Clinical Hepatic Encephalopathy Staging Scale (CHESS) 27 was designed to monitor the severity of HE on a scale from 0 (low) to 9 (high) and with aim to reduce interobserver variability. These questions have been used in two recent randomized clinical trials (Simon-Talero et al and Rockey et al) 28,29.

4. MO-Log

The Modified-orientation log is an 8-question adaptation of the orientation developed by Novack et al30 in traumatic brain injury and extends it to hepatic encephalopathy. Its questions are heavily weighted towards disorientation to time, which is the earliest form of disorientation in OHE. The subjects are asked a particular question and responses to logical cues and multiple choice questions are studied in case the orientation question is not answered correctly; the highest score is 24 and lowest is 0. In their study Salam et al concluded that the Mo-log is a valid tool for assessing severity and is better than West-Haven criteria in predicting outcomes in hospitalized hepatic encephalopathy patients and the change in MO-log over the first 24 hours of hospitalization was especially important in predicting outcomes31.

5. GCS

For deeper grades of coma or in which patients are not verbally responsive, there are no specific HE questionnaires but the validated Glasgow Coma Scale (GCS) can be utilized. GCS adds to the assessment of severe HE by providing a wider separation for cases where grades III and IV are present. The study by Hassanein et al indicates weak performance of the GCS in lower grades of HE26.

Summary of overt HE grading

Therefore the current grading of overt HE requires further study beyond the West-Haven criteria and its modifications. Simple questionnaires such as CHESS and MO-log can divide the patients’ mental status into 9 and 24 levels respectively. Glasgow Coma scale can be used for patients who are not responsive to questionnaires.

DIAGNOSTIC TESTING FOR COVERT HEPATIC ENCEPHALOPATHY

Standardization of screening tools for diagnosis of covert HE remains a vital issue. The Hepatic Encephalopathy Consensus Group at the World Congress of Gastroenterology in 1998 endorsed the psychometric hepatic encephalopathy score (PHES) as the gold standard for diagnosing CHE1. Over the past decade, several drawbacks of this testing system have been identified such as test administration and scoring in the outpatient setting. Although the PHES is popular in Europe, it has failed to gain widespread acceptance in the United States, mainly because of copyright issues and the lack of availability of testing material9.

CHE does not have a clinically apparent profile hence clinical diagnostic testing cannot be used. The ideal test for CHE diagnosis would be a quick, cheap, reliable, readily available, easy to administer test that accurately predict outcomes. The consequences of CHE on daily living even though patients are asymptomatic32 has led to the need for screening tests and early detection. Neuropsychological and neurophysiological methods have been the most trusted and widely used tests to diagnose CHE1,4,5. These tests should be easy to use, quantifiable and assess the cognitive domain: attention deficit and slow information processing, which are the most prominent disturbances in covert HE33. A number of computerized psychometric testing systems are being validated for the diagnosis of CHE, but they are not yet at a stage at which they can be implemented or endorsed globally.

NEUROPSYCHOMETRIC TESTS

Neuropsychological or neuropsychometric tests include both ‘paper and pencil’ tests and computerized tests that can be used to identify impairments in visuo-spatial functioning, attention, processing speed and response inhibition34. These tests are cheap, easy to administer and do not require experienced personnel or expensive equipment. However, their dependence on a patient’s age and education, total testing time and applicability restricted to lower grades of HE confers a disadvantage to diagnosis of HE. Present international consensus recommends use of the PHES or RBANS for diagnosing and monitoring CHE depending on availability of local normative data35.

PAPER-AND-PENCIL TESTS

1. PHES

The Psychometric Hepatic Encephalopathy Score (PHES) is the current ‘gold standard’ pencil-and-paper test battery for the psychometric evaluation of patients with HE, standardized and validated by Weissenborn and colleagues34. This battery measures psychomotor speed and precision, visual perception, visuo-spatial orientation, visual construction, concentration, attention and memory, is simple to perform and can be completed in less than 20 minutes36. The PHES initially comprised of seven tests but the desire for a shorter battery and the poor sensitivity of some of the tests led to the introduction of a revised battery called the Portosystemic Encephalopathy (PSE) Syndrome Test, which includes the line tracing test (LTT), serial dotting test (SDT), digit symbol test (DST) and number connection test A and B (NCT A and B). The sensitivity and specificity of the PHES compared with the standard method of determining HE grade were 96% and 100%, respectively36. Standard normative data of the PHES have been developed in German, Spanish and Italian. Thus, the PHES is predominantly used for detecting CHE in Europe24. Performing this battery can be time consuming and prone to bias from disturbance, mood and interaction with the tester37. This is not available directly in the US and there are no nationwide norms for this. However, it can be obtained through ISHEN.

2. RBANS

The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) is a 20–25 minutes paper-and-pencil battery used to diagnose neurocognitive disorders such as dementia, traumatic brain injury, stroke, multiple sclerosis and bipolar disorder. It evaluates global cognitive functioning based on language, visual perception, attention, immediate memory, and delayed memory. Although a few studies have now confirmed its usefulness in characterizing cognitive impairment in liver transplant candidates38,39 and the International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) recommended its use in patients for CHE35, there are limited data to support its use since two of its domains, delayed memory and language, are not usually impaired in CHE. A modified version of the RBANS that takes about 20- 25 minutes to administer has been designed to focus specifically on the cognitive changes that occur in patients with OHE35 and has proven to be effective in screening patients for CHE39. The RBANS is available for a fee in the US through psychological corporation inc.

COMPUTERIZED TESTS

Paper and pencil tests rely heavily on the motor function of the patient and involve multiple cognitive functions for their successful completion. However, computerized testing affords greater control over task stimuli and standardization of presentation, allowing specific cognitive processes to be assessed40.

1. ICT

The Inhibitory Control Test (ICT) is a computerized test of attention and response inhibition. It consists of a continuous stream of letters presented on a computer screen every 500 msec with targets (alternating X and Y) and lures (non-target X and Y). The percentage of targets and lures responded to, as well as reaction time, are recorded. A study by Bajaj et al showed that lure responses greater than five out of forty attempts could detect CHE with high sensitivity. Lower lure response, higher target response, and shorter reaction times indicate a good performance41. However, another study reported that lures alone were not sensitive in detecting MHE; target accuracy and lures weighted by target accuracy showed better discriminating values between healthy controls and patients with MHE42. Studies evaluating driving showed that ICT performance was significantly associated with driving simulator performance and traffic accidents41,43. ICT is a sensitive, inexpensive, and easily administered test with good external validity and test-retest reliability, which makes it a good candidate as a diagnostic tool in CHE44. Like other neuropsychological measures, the ICT is influenced by prior exposure42. This is available for free download at www.hecme.tv.

2. CDR

The Cognitive Drug Research (CDR) battery assesses five cognitive areas including attention power, attention continuity, speed of memory and quality of episodic and working memory via a set of increasingly complex tasks based on yes/no responses that are inputted via a decision box by the patient after the initial learning period. The CDR has shown good correlation with the gold standard PHES test, is well validated across population norms and disease states including many forms of dementia and psychiatric conditions, and has recently been validated in patients with HE40. It does not have US-based norms but is available for a fee from the UK.

3. Scan Test

Montagnese et al from Italy assessed the usefulness of the Scan package, a three-level-difficulty computerised reaction time test, to diagnose varying degrees of hepatic encephalopathy45. The first level is a simple reaction time (sRT) where the subject is asked to respond to a series of visual stimuli (an asterisk on the computer screen) by pressing the spacebar on the keyboard. Level two is the choice reaction time (cRT) where the subject is presented with either the number 1 or the number 3 on the computer screen and asked to press 1 or 3 on the keyboard, accordingly. Level three is the scan reaction time (ScanRT), which is a digit recognition task based on the Sternberg paradigm and has previously been shown to be a useful test in patients with cirrhosis17,46. The subject is presented with 36 consecutive pairs of numbers, and asked to press 1 on the keyboard if there are digits in common or press 3 if there are not. For all three levels, the number of correct responses, expressed as a percentage of the total number of stimuli (accuracy), and the accuracy-adjusted, average RT (ms) are calculated. Limitations to this study included that while the Scan test software provides an overall Z score, which is corrected for age/educational attainment, the presented weighed RTs were not normalised, and should be considered valid for populations of patients with cirrhosis similar to that used in this study45. Amodio and colleagues found that, among various types of psychometric tests such as the Trail-making Tests and Symbol Digit Modality Tests, the scan test was the most closely related to central brain atrophy47. About 50% of cirrhotic patients performed poorly on the scan test, making it valuable in detecting the neuropsychological impairment caused by cirrhosis. Furthermore, patients who had history of OHE performed significantly worse than those who never had a bout of OHE24. This however, is not available in the US.

4. STROOP App test

The Stroop smartphone application (EncephalApp_Stroop) was used by Bajaj et al as a valid, reliable tool to screen for CHE48. The Stroop task is a test of psychomotor speed and cognitive flexibility that evaluates the functioning of the anterior attention system and has been found to be sensitive for the detection of cognitive impairment in CHE49. The EncephalApp_Stroop (available on iTunes for free download) is easy to administer, simple to score and interpret. This new app has cut-offs that are age-specific but need to be validated in other populations. The details of its download, interpretation and administration can be viewed as webcasts at www.chronicliverdisease.org.

NEUROPHYSIOLOGICAL TESTS

1. CFF

Critical flicker frequency (CFF) can detect a range of neuropsychological abnormalities from visual signal processing to cognitive functions making it a valuable tool in various fields including hepatology, neurology, psychiatry, and ophthalmology15,50,51. Patients are shown light pulses at an initial frequency of 60 Hz gradually reduced by 0.1 Hz decrements per second. Patients are asked to identify the time at which the apparently steady fused light begins to flicker. A critical flicker frequency of below 39 Hz diagnoses CHE with high sensitivity and specificity and test results correlate positively with those of paper-and-pencil neuropsychometric test52. Most published studies agree that the sensitivity and specificity of CFF diagnosing CHE is 80% and 65% respectively53. The CFF has the advantage of not being dependent on language, verbal fluency, numeracy or numerics, and therefore studies into its use have been performed in the United States, Europe and Asia37. It is a simple, easy-to-use, and reliable tool that is independent of education, gender, age, and literacy.

In recent studies by Sharma et al, the CFF has been evaluated as an objective measure for grading CHE as well as assessing recovery of patients with cirrhosis from sedation after endoscopy53,54. Other studies assessed the use of CFF as a marker for objective HE evaluation in patients undergoing transjugular intrahepatic portosystemic shunt52,55. Romero-Gomez et al in their study found that CFF together with Child-Pugh class can predict the development of HE grade II and I in follow-up15. However, further validation and standardization studies are needed to determine its use and applicability in differentiating between HE grades 0 and I. It is not useful in grade III or IV HE either because patients’ attention and cooperation are required. Thus CFF has not been established as a diagnostic tool in OHE. A meta-analysis by Torlot et al37 has shown that CFF is a diagnostically accurate test, which could be used as an adjunct to conventional psychometric test batteries, such as PHES, but could only become a replacement screening test if further studies show an improvement in sensitivity.

2. EEG

Similar to clinical grading, the electroencephalogram (EEG) classifies HE in five grades of severity from normal to coma. In published studies, the diagnostic sensitivity for HE ranges between 43% and 100%34. In mild HE, the increase in confusion is associated with the initial EEG tracings that reveal posterior dominant alpha rhythm slowing, which is typically followed by a gradual appearance of theta and high-amplitude irregular delta waves as the HE progresses into coma. This neurophysiological method is associated with both inter- and intra-observer variability leading some to suggest a lack of objectivity56. An alternative objective approach is spectral analysis of the EEG, which is a computerized analysis of the frequency distribution in the EEG. Spectral analysis of the EEG is a simple technique, is more reliable than visual EEG reading, and has prognostic value for the development of HE and mortality in cirrhotic patients57,58. Digital analysis of the EEG analyses EEG in various regions of the brain making more sensitive than conventional or spectral EEG in detecting early HE. 85% of patients with no clinical symptoms of HE show abnormalities on digital analysis proving its high sensitivity for functional cerebral alterations59.

3. Evoked Potentials

Visual, auditory and somatosensory-evoked potentials (EPs) have been investigated in patients with HE but their use is limited in patients with OHE due to patient cooperation. Both auditory and visual P300 have been shown to have diagnostic potential in mild HE but are nonspecific to HE and not recommended because of inconsistent results60. The P300 is an event-related potential that is elicited by low-probability target items interspersed among high-probability nonstimuli. In response to the oddball stimuli, the brain shows an EEG recognition response at approximately 300 to 600 milliseconds. A delay response greater than 300 milliseconds indicates brain impairment24. Auditory P300 potentials have been used independently and may have value in the diagnosis of CHE. However, the absence of clear cutoffs and guidelines for the sensitivity and specificity that define CHE limit their clinical usefulness. Some researchers suggest that expensive equipment, low sensitivity, and the lack of accompanying behavioral information are drawbacks of these methods61,62.

Summary for covert HE testing in clinical practice

A summary of relative advantages, disadvantages and availability of certain tests are listed in table 1. A suggested checklist and order of testing that could be used for covert HE in US-based clinic is also displayed in table 2 and figure 1 respectively.

Table 1.

Summary of Tests That Could be Used in Clinical Practice

Advantages Disadvantages Logistics in the US Time required
Paper Pencil
PHES Validated in several non-US populations Norms not available in the US Need psychologists to order 15–20 minutes
Combination of NCT-A, NCT-B, DST and BDT Recommended for populations without PHES norms Block design test can take longer in more impaired patients Need psychologists to order 25–30 minutes
RBANS Has US-based norms Not performed well since two domains are not affected in covert HE Need psychologists to order and interpret 30–35 minutes
Computerized
Inhibitory control test Does not require psychologists Validated in a few centers Highly functional patients required Free download at www.hecme.tv 15–20 minutes
SCAN test Does not require psychologists Not validated in the USA Not available 20 minutes
EncephalApp_ Stroop Can be given on a mobile platform as an app Only validated in two centers Cannot be done in color-blind subjects Available for free download at the iTunes app store 5 minutes
Neurophysiological
EEG Easy to perform across all levels of HE severity Local norms for each hospital available Need neurological support Can take hours including interpretation
Evoked potentials Sensitive for diagnosis Local norms for each hospital available Need neurological support 30–60 minutes
Critical Flicker Frequency Can be given bedside or mobile Expensive equipment Available from several companies 10–15 minutes

Table 2.

Suggested Checklist Pertaining to Covert HE testing (the answer to most questions should be yes before proceeding to testing)

Yes No
Pre-testing Checklist
Patients who are at risk for accidents or job-related mistakes, have cognitive complaints or poor quality of life
No current overt HE (alert, oriented, MMSE >25)
Not on psycho-active drugs (chronic anti-depressants are acceptable)
No uncontrolled neuro-psychiatric disorders
Patient is able to comprehend cognitive test procedures
Adequate vision (corrected with spectacles), hearing and motor strength to perform tasks
Counseled patient and relatives regarding potential results
Testing Techniques and Environment
Quiet environment with relaxed patients
Using techniques with locally available normative values
Trained examiner using tests with scripts or protocols
Post-Testing Questions
Counseled patient and relatives regarding results and performance
Offered treatment trial if requested

Figure 1.

Figure 1

Suggested Practical Covert HE treatment strategy in order

Conclusions

A survey among members of the American Association for the Study of Liver Diseases (AASLD) showed that 72% tested less than half their patients for CHE, despite 84% acknowledging that CHE is a significant problem. Furthermore, 85% said that if clinical staff could perform a quick, accurate test, this would increase the likelihood that people would test for CHE63. There is no single ideal test that accurately covers the spectrum of HE, from minimal changes to deep coma26. EEG, which can be done across the spectrum of HE, has not been shown to have a high degree of precision for metabolic encephalopathies64. The rest of the tests either work at the beginning or the end of the spectrum of neuro-cognitive impairment in cirrhosis (SONIC)65. Tests for covert HE are slowly but steadily making their way into the mainstream with the focus being on end-user ease and cost-effective methods of implementation of these strategies to maximize local resources. Continued research into this very important field is continuing and further validation studies will be available soon.

Footnotes

Compliance with Ethics Guidelines

Conflict of Interest

Dr. Bajaj serves as a consultant for Otsuka. Dr. Bajaj received grants from Grifols, Otsuka, and Salix. In addition, Dr. Bajaj received honoraria from Abbott, Otsuka, Grifols, and Merz.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by the author.

Reference

  • 1.Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei A. Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: Final report of the working party at the 11th world congresses of gastroenterology, vienna, 1998. Hepatology. 2002;35(3):716–721. doi: 10.1053/jhep.2002.31250. [DOI] [PubMed] [Google Scholar]
  • 2.Albrecht J. Hepatic encephalopathy in our genes? Ann Intern Med. 2010;153(5):335–336. doi: 10.7326/0003-4819-153-5-201009070-00008. [DOI] [PubMed] [Google Scholar]
  • 3.Bajaj J. Minimal hepatic encephalopathy matters in daily life. World Journal of Gastroenterology. 2008;14(23):3609–3615. doi: 10.3748/wjg.14.3609. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Ortiz M, Jacas C, Córdoba J. Minimal hepatic encephalopathy: Diagnosis, clinical significance and recommendations. J Hepatol. 2005;42(Suppl)(1):S45–S53. doi: 10.1016/j.jhep.2004.11.028. [DOI] [PubMed] [Google Scholar]
  • 5.Bajaj J. Management options for minimal hepatic encephalopathy. Expert review of gastroenterology hepatology. 2008;2(6):785–790. doi: 10.1586/17474124.2.6.785. [DOI] [PubMed] [Google Scholar]
  • 6.Mullen KF, Mullen KD, et al. An algorithm for the management of hepatic encephalopathy. Semin Liver Dis. 27 32-+ [Google Scholar]
  • 7.Bajaj J, Hafeezullah M, Hoffmann R, Saeian K. Minimal hepatic encephalopathy: A vehicle for accidents and traffic violations. Am J Gastroenterol. 2007;102(9):1903–1909. doi: 10.1111/j.1572-0241.2007.01424.x. [DOI] [PubMed] [Google Scholar]
  • 8.Kircheis G, Knoche A, Hilger N, et al. Hepatic encephalopathy and fitness to drive. Gastroenterology. 2009;137(5) doi: 10.1053/j.gastro.2009.08.003. 1706-15.e1. [DOI] [PubMed] [Google Scholar]
  • 9.Prakash R, Brown T, Mullen K. Minimal hepatic encephalopathy and driving: Is the genie out of the bottle? Am J Gastroenterol. 2011;106(8):1415–1416. doi: 10.1038/ajg.2011.154. [DOI] [PubMed] [Google Scholar]
  • 10.Prakash R, Mullen K. Is poor quality of life always present with minimal hepatic encephalopathy? Liver international. 2011;31(7):908–910. doi: 10.1111/j.1478-3231.2011.02532.x. [DOI] [PubMed] [Google Scholar]
  • 11.Groeneweg M, Quero JC, De Bruijn I, et al. Subclinical hepatic encephalopathy impairs daily functioning. Hepatology. 1998;28(1):45–49. doi: 10.1002/hep.510280108. [DOI] [PubMed] [Google Scholar]
  • 12.Schomerus H, Hamster W. Quality of life in cirrhotics with minimal hepatic encephalopathy. Metab Brain Dis. 2001;16(1–2):37–41. doi: 10.1023/a:1011610427843. [DOI] [PubMed] [Google Scholar]
  • 13.Das A, Dhiman RK, Saraswat VA, Verma M, Naik SR. Prevalence and natural history of subclinical hepatic encephalopathy in cirrhosis. J Gastroenterol Hepatol. 2001;16(5):531–535. doi: 10.1046/j.1440-1746.2001.02487.x. [DOI] [PubMed] [Google Scholar]
  • 14.Mullen K, Prakash R. New perspectives in hepatic encephalopathy. Clin Liver Dis. 2012;16(1):1–5. doi: 10.1016/j.cld.2012.01.001. [DOI] [PubMed] [Google Scholar]
  • 15.Romero-Gómez M, Córdoba J, Jover R, et al. Value of the critical flicker frequency in patients with minimal hepatic encephalopathy. Hepatology. 2007;45(4):879–885. doi: 10.1002/hep.21586. [DOI] [PubMed] [Google Scholar]
  • 16.Saxena N, Bhatia M, Joshi Y, Garg P, Dwivedi S, Tandon R. Electrophysiological and neuropsychological tests for the diagnosis of subclinical hepatic encephalopathy and prediction of overt encephalopathy. Liver. 2002;22(3):190–197. doi: 10.1034/j.1600-0676.2002.01431.x. [DOI] [PubMed] [Google Scholar]
  • 17.Amodio P, Del Piccolo F, Marchetti P, et al. Clinical features and survivial of cirrhotic patients with subclinical cognitive alterations detected by the number connection test and computerized psychometric tests. Hepatology. 1999;29(6):1662–1667. doi: 10.1002/hep.510290619. [DOI] [PubMed] [Google Scholar]
  • 18. Bajaj JS, Cordoba J, Mullen KD, et al. Review article: The design of clinical trials in hepatic encephalopathy--an international society for hepatic encephalopathy and nitrogen metabolism (ISHEN) consensus statement. Alimentary pharmacology therapeutics. 2011;33(7):739–747. doi: 10.1111/j.1365-2036.2011.04590.x. ●●● Consensus on the design of clinical trials in hepatic encephalopathy
  • 19.Khungar V, Poordad F. Hepatic encephalopathy. Clin Liver Dis. 2012;16(2):301–320. doi: 10.1016/j.cld.2012.03.009. [DOI] [PubMed] [Google Scholar]
  • 20.Nicolao F, Efrati C, Masini A, Merli M, Attili AF, Riggio O. Role of determination of partial pressure of ammonia in cirrhotic patients with and without hepatic encephalopathy. J Hepatol. 2003;38(4):441–446. doi: 10.1016/s0168-8278(02)00436-1. [DOI] [PubMed] [Google Scholar]
  • 21.Ong JP, Aggarwal A, Krieger D, et al. Correlation between ammonia levels and the severity of hepatic encephalopathy. Am J Med. 2003;114(3):188–193. doi: 10.1016/s0002-9343(02)01477-8. [DOI] [PubMed] [Google Scholar]
  • 22.Gundling F, Zelihic E, Seidl H, et al. How to diagnose hepatic encephalopathy in the emergency department. Ann Hepatol. 2013;12(1):108–114. [PubMed] [Google Scholar]
  • 23. Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362(12):1071–1081. doi: 10.1056/NEJMoa0907893. ●●● Randomized controlled trial of rifaximin in prevention of recurrence of overt hepatic encephalopathy
  • 24.Sakamoto M, Perry W, Hilsabeck RC, Barakat F, Hassanein T. Assessment and usefulness of clinical scales for semiquantification of overt hepatic encephalopathy. Clin Liver Dis. 2012;16(1):27–42. doi: 10.1016/j.cld.2011.12.005. [DOI] [PubMed] [Google Scholar]
  • 25.Hassanein TI, Hilsabeck RC, Perry W. Introduction to the hepatic encephalopathy scoring algorithm (HESA) Dig Dis Sci. 2008;53(2):529–538. doi: 10.1007/s10620-007-9895-0. [DOI] [PubMed] [Google Scholar]
  • 26.Hassanein T, Blei AT, Perry W, et al. Performance of the hepatic encephalopathy scoring algorithm in a clinical trial of patients with cirrhosis and severe hepatic encephalopathy. Am J Gastroenterol. 2009;104(6):1392–1400. doi: 10.1038/ajg.2009.160. [DOI] [PubMed] [Google Scholar]
  • 27.Ortiz M, Cordoba J, Doval E, et al. Development of a clinical hepatic encephalopathy staging scale. Aliment Pharmacol Ther. 2007;26(6):859–867. doi: 10.1111/j.1365-2036.2007.03394.x. [DOI] [PubMed] [Google Scholar]
  • 28. Rockey DC, Vierling JM, Mantry P, et al. Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. Hepatology. 2013 doi: 10.1002/hep.26611. ●●● Randomized controlled trial on hepatic encephalopathy recurrence.
  • 29. Simon-Talero M, Garcia-Martinez R, Torrens M, et al. Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy: A randomized double-blind study. J Hepatol. 2013 doi: 10.1016/j.jhep.2013.07.020. ● Study on albumin in the reduction of hospital stay
  • 30.Novack T. [accessed january 2010];the center for outcome measurement in brain injury. available at: Http://Www.tbims.org/combi/olog.
  • 31. Salam M, Matherly S, Farooq IS, et al. Modified-orientation log to assess hepatic encephalopathy. Aliment Pharmacol Ther. 2012;35(8):913–920. doi: 10.1111/j.1365-2036.2012.05038.x. ●● Simple questionnaire to grade overt hepatic encephalopathy
  • 32.Quero JC, Schalm SW. Subclinical hepatic encephalopathy. Semin Liver Dis. 1996;16(3):321–328. doi: 10.1055/s-2007-1007244. [DOI] [PubMed] [Google Scholar]
  • 33.Córdoba J. New assessment of hepatic encephalopathy. J Hepatol. 2011;54(5):1030–1040. doi: 10.1016/j.jhep.2010.11.015. [DOI] [PubMed] [Google Scholar]
  • 34.Chronic Liver Disease Foundation. Hepatic encephalopathy: A review of diagnostic methods. 2013. Jul 15, [Google Scholar]
  • 35.Randolph C, Hilsabeck R, Kato A, et al. Neuropsychological assessment of hepatic encephalopathy: ISHEN practice guidelines. Liver Int. 2009;29(5):629–635. doi: 10.1111/j.1478-3231.2009.02009.x. [DOI] [PubMed] [Google Scholar]
  • 36.Weissenborn K, Ennen JC, Schomerus H, Ruckert N, Hecker H. Neuropsychological characterization of hepatic encephalopathy. J Hepatol. 2001;34(5):768–773. doi: 10.1016/s0168-8278(01)00026-5. [DOI] [PubMed] [Google Scholar]
  • 37. Torlot FJ, McPhail MJW, Taylor-Robinson SD. Meta-analysis: The diagnostic accuracy of critical flicker frequency in minimal hepatic encephalopathy. Aliment Pharmacol Ther. 2013;37(5):527–536. doi: 10.1111/apt.12199. ●● Critical flicker frequency in minimal hepatic encephalopathy
  • 38.Mooney S, Hasssanein TI, Hilsabeck RC, et al. Utility of the repeatable battery for the assessment of neuropsychological status (RBANS) in patients with end-stage liver disease awaiting liver transplant. Arch Clin Neuropsychol. 2007;22(2):175–186. doi: 10.1016/j.acn.2006.12.005. [DOI] [PubMed] [Google Scholar]
  • 39.Meyer T, Eshelman A, Abouljoud M. Neuropsychological changes in a large sample of liver transplant candidates. Transplant Proc. 2006;38(10):3559–3560. doi: 10.1016/j.transproceed.2006.10.050. [DOI] [PubMed] [Google Scholar]
  • 40.Mardini H, Saxby BK, Record CO. Computerized psychometric testing in minimal encephalopathy and modulation by nitrogen challenge and liver transplant. Gastroenterology. 2008;135(5):1582–1590. doi: 10.1053/j.gastro.2008.06.043. [DOI] [PubMed] [Google Scholar]
  • 41.Bajaj JS, Hafeezullah M, Franco J, et al. Inhibitory control test for the diagnosis of minimal hepatic encephalopathy. Gastroenterology. 2008;135(5) doi: 10.1053/j.gastro.2008.07.021. 1591-1600.e1. [DOI] [PubMed] [Google Scholar]
  • 42.Amodio P, Ridola L, Schiff S, et al. Improving the inhibitory control task to detect minimal hepatic encephalopathy. Gastroenterology. 2010;139(2):510–518. doi: 10.1053/j.gastro.2010.04.057. 518.e1-2. [DOI] [PubMed] [Google Scholar]
  • 43.Bajaj JS, Hafeezullah M, Zadvornova Y, et al. The effect of fatigue on driving skills in patients with hepatic encephalopathy. Am J Gastroenterol. 2009;104(4):898–905. doi: 10.1038/ajg.2009.7. [DOI] [PubMed] [Google Scholar]
  • 44.Montgomery J, Bajaj J. Advances in the evaluation and management of minimal hepatic encephalopathy. Curr Gastroenterol Rep. 2011;13(1):26–33. doi: 10.1007/s11894-010-0150-z. [DOI] [PubMed] [Google Scholar]
  • 45. Montagnese S, Schiff S, Turco M, et al. Simple tools for complex syndromes: A three-level difficulty test for hepatic encephalopathy. Digestive and Liver Disease. 2012;44(11):957–960. doi: 10.1016/j.dld.2012.06.010. ● Scan test in covert hepatic encephalopathy
  • 46.Amodio P, Marchetti P, Del Piccolo F, et al. Study on the sternberg paradigm in cirrhotic patients without overt hepatic encephalopathy. Metab Brain Dis. 1998;13(2):159–172. doi: 10.1023/a:1020665431411. [DOI] [PubMed] [Google Scholar]
  • 47.Amodio P, Pellegrini A, Amista P, et al. Neuropsychological-neurophysiological alterations and brain atrophy in cirrhotic patients. Metab Brain Dis. 2003;18(1):63–78. doi: 10.1023/a:1021982719654. [DOI] [PubMed] [Google Scholar]
  • 48. Bajaj JS, Thacker LR, Heuman DM, et al. The stroop smartphone application is a short and valid method to screen for minimal hepatic encephalopathy. Hepatology. 2013;58(3):1122–1132. doi: 10.1002/hep.26309. ●● Stroop app for minimal hepatic encephalopathy
  • 49.Amodio P, Schiff S, Del Piccolo F, Mapelli D, Gatta A, Umilta C. Attention dysfunction in cirrhotic patients: An inquiry on the role of executive control, attention orienting and focusing. Metab Brain Dis. 2005;20(2):115–127. doi: 10.1007/s11011-005-4149-3. [DOI] [PubMed] [Google Scholar]
  • 50.Wunsch E, Post M, Gutkowski K, et al. Critical flicker frequency fails to disclose brain dysfunction in patients with primary biliary cirrhosis. Dig Liver Dis. 2010;42(11):818–821. doi: 10.1016/j.dld.2010.03.017. [DOI] [PubMed] [Google Scholar]
  • 51.Lauridsen MM, Jepsen P, Vilstrup H. Critical flicker frequency and continuous reaction times for the diagnosis of minimal hepatic encephalopathy: A comparative study of 154 patients with liver disease. Metab Brain Dis. 2011;26(2):135–139. doi: 10.1007/s11011-011-9242-1. [DOI] [PubMed] [Google Scholar]
  • 52.Kircheis G, Bode JG, Hilger N, Kramer T, Schnitzler A, Haussinger D. Diagnostic and prognostic values of critical flicker frequency determination as new diagnostic tool for objective HE evaluation in patients undergoing TIPS implantation. Eur J Gastroenterol Hepatol. 2009;21(12):1383–1394. doi: 10.1097/MEG.0b013e328310e0c3. [DOI] [PubMed] [Google Scholar]
  • 53.Sharma P, Sharma BC, Sarin SK. Critical flicker frequency for diagnosis and assessment of recovery from minimal hepatic encephalopathy in patients with cirrhosis. Hepatobiliary Pancreat Dis Int. 2010;9(1):27–32. [PubMed] [Google Scholar]
  • 54.Sharma P, Singh S, Sharma BC, et al. Propofol sedation during endoscopy in patients with cirrhosis, and utility of psychometric tests and critical flicker frequency in assessment of recovery from sedation. Endoscopy. 2011;43(5):400–405. doi: 10.1055/s-0030-1256182. [DOI] [PubMed] [Google Scholar]
  • 55.Biecker E, Hausdorfer I, Grunhage F, Strunk H, Sauerbruch T. Critical flicker frequency as a marker of hepatic encephalopathy in patients before and after transjugular intrahepatic portosystemic shunt. Digestion. 2011;83(1–2):24–31. doi: 10.1159/000288522. [DOI] [PubMed] [Google Scholar]
  • 56.Amodio P, Pellegrini A, Ubiali E, et al. The EEG assessment of low-grade hepatic encephalopathy: Comparison of an artificial neural network-expert system (ANNES) based evaluation with visual EEG readings and EEG spectral analysis. Clin Neurophysiol. 2006;117(10):2243–2251. doi: 10.1016/j.clinph.2006.06.714. [DOI] [PubMed] [Google Scholar]
  • 57.Amodio P, Marchetti P, Del Piccolo F, et al. Spectral versus visual EEG analysis in mild hepatic encephalopathy. Clin Neurophysiol. 1999;110(8):1334–1344. doi: 10.1016/s1388-2457(99)00076-0. [DOI] [PubMed] [Google Scholar]
  • 58.Amodio P, Del Piccolo F, Petteno E, et al. Prevalence and prognostic value of quantified electroencephalogram (EEG) alterations in cirrhotic patients. J Hepatol. 2001;35(1):37–45. doi: 10.1016/s0168-8278(01)00129-5. [DOI] [PubMed] [Google Scholar]
  • 59.Kullmann F, Hollerbach S, Lock G, Holstege A, Dierks T, Scholmerich J. Brain electrical activity mapping of EEG for the diagnosis of (sub)clinical hepatic encephalopathy in chronic liver disease. Eur J Gastroenterol Hepatol. 2001;13(5):513–522. doi: 10.1097/00042737-200105000-00009. [DOI] [PubMed] [Google Scholar]
  • 60.Montagnese S, Amodio P, Morgan MY. Methods for diagnosing hepatic encephalopathy in patients with cirrhosis: A multidimensional approach. Metab Brain Dis. 2004;19(3–4):281–312. doi: 10.1023/b:mebr.0000043977.11113.2a. [DOI] [PubMed] [Google Scholar]
  • 61.Bajaj JS. Review article: The modern management of hepatic encephalopathy. Aliment Pharmacol Ther. 2010;31(5):537–547. doi: 10.1111/j.1365-2036.2009.04211.x. [DOI] [PubMed] [Google Scholar]
  • 62.Montagnese S, Jackson C, Morgan MY. Spatio-temporal decomposition of the electroencephalogram in patients with cirrhosis. J Hepatol. 2007;46(3):447–458. doi: 10.1016/j.jhep.2006.10.015. [DOI] [PubMed] [Google Scholar]
  • 63.Bajaj JS, Etemadian A, Hafeezullah M, Saeian K. Testing for minimal hepatic encephalopathy in the united states: An AASLD survey. Hepatology. 2007;45(3):833–834. doi: 10.1002/hep.21515. [DOI] [PubMed] [Google Scholar]
  • 64.Kaplan PW. The EEG in metabolic encephalopathy and coma. J Clin Neurophysiol. 2004;21(5):307–318. [PubMed] [Google Scholar]
  • 65. Bajaj J, Wade J, Sanyal A. Spectrum of neurocognitive impairment in cirrhosis: Implications for the assessment of hepatic encephalopathy. Hepatology. 2009;50(6):2014–2021. doi: 10.1002/hep.23216. ●●● Spectrum of neuro-cognitive impairment in cirrhosis

RESOURCES